Comparable COVID ‐19 outcomes with current use of GLP ‐1 receptor agonists, DPP ‐4 inhibitors or SGLT ‐2 inhibitors among patients with diabetes who tested positive for SARS‐CoV ‐2

Changes in SGLT2i and GLP-1RA real-world initiator profiles following cardiovascular outcome trials: A Danish nationwide population-based study

(2020) Jakob S. Knudsen et al.   PLoS One

Clinical Characteristics and Outcomes of Patients With Diabetes and COVID-19 in Association With Glucose-Lowering Medication

(2020) Yuchen Chen et al.   DIABETES CARE

Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study

(2020) Bertrand Cariou et al.   DIABETOLOGIA

Potential Benefits and Harms of Novel Antidiabetic Drugs During COVID-19 Crisis

(2020) Maria Mirabelli et al.   International Journal of Environmental Research and Public Health

Factors associated with COVID-19-related death using OpenSAFELY

(2020) Elizabeth J. Williamson et al.   NATURE

Practical recommendations for the management of diabetes in patients with COVID-19

(2020) Stefan R Bornstein et al.   Lancet Diabetes & Endocrinology

Existing Data Sources in Clinical Epidemiology: The Danish COVID-19 Cohort

(2020) Anton Pottegård et al.   Clinical Epidemiology

Sitagliptin Treatment at the Time of Hospitalization Was Associated With Reduced Mortality in Patients With Type 2 Diabetes and COVID-19: A Multicenter, Case-Control, Retrospective, Observational Study

(2020) Sebastiano Bruno Solerte et al.   DIABETES CARE

Characteristics and predictors of hospitalization and death in the first 11 122 cases with a positive RT-PCR test for SARS-CoV-2 in Denmark: a nationwide cohort

(2020) Mette Reilev et al.   INTERNATIONAL JOURNAL OF EPIDEMIOLOGY

Use of dipeptidyl peptidase‐4 inhibitors and risk of splanchnic vein thrombosis: A Danish nationwide new‐user active comparator cohort study

(2020) Anton Pottegård et al.   DIABETES OBESITY & METABOLISM